golodirsen (Vyondys 53) Report issue

Gene therapy Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now
Golodirsen, sold under the brand name Vyondys 53, is a medication used for the treatment of Duchenne muscular dystrophy (DMD). It is an antisense oligonucleotide drug of phosphorodiamidate morpholino oligomer (PMO) chemistry.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$1222.1100 - $1591.9600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

srp-4053

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Muscular Dystrophy, Duchenne (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Muscular Dystrophy, Duchenne (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue